Effects of oral contraceptives on breast epithelial proliferation

Breast Cancer Research and Treatment

Volumn 65, Issue 2, 2001, Pages 163-169

  Isaksson, E ^a   Schoultz, E V ^a   Odlind, V ^a   Soderqvist G ^a   Csemiczky, G ^a   Carlstrom K ^a   Skoog, L ^a   Schoultz, B V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast epithelial proliferation; Levonorgestrel; Oral contraceptives; Progestogen

Indexed keywords

ANDROGEN; GESTAGEN; KI 67 ANTIGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN TISSUE; MITOGENICITY; NORMAL HUMAN; PREMENOPAUSE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIGENS, NUCLEAR; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; BREAST; CASE-CONTROL STUDIES; CELL DIVISION; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NUCLEAR PROTEINS; PROGESTERONE;

EID: 0035124479     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006482418082     Document Type: Article

References (35)

1. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies
2. Increased cell division as a cause of human cancer
3. The dose-effect relationship between 'unopposed' estrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk
4. Progestin effect on cell proliferation and 17-β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture
5. A correlative morphologic study of human breast and endometrium in the menstrual cycle
6. Proliferation of breast epithelial cells in healthy women during the menstrual cycle
7. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast
8. Oral contraceptive use influences resting breast proliferation
9. Aspiration biopsy in diagnosis of palpable lesions of the breast. Critical review of 3479 consecutive biopsies
10. Breast fine needle aspiration cytology. Utility as a screening tool for clinically palpable lesions
11. Analysis of hormone receptors and proliferation fraction in hne-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment
12. Immunocytochemical analysis of receptors for estrogen and progesterone in fine needle aspirates from human breast carcinomas
13. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle
14. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
15. Rosenborg L: Serum levels of 4-androstene-3,17-dione in menstruating and postmenopausal women. Evaluation of a radioimmunoassay and correlation to bone mineral content and endometrial pathology
16. Orchidectomy or estrogen treatment in prostatic cancer: Effects on serum levels of adrenal androgens and related steroids
17. Calculation of free and bound fractions of testosterone and estradiol-17β to plasma proteins at body temperature
18. Plasma levels of d-Norgestrel estradiol and progesterone during treatment with silastic implants containing d-Norgestrel
19. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmological study
20. Frequency and distribution of oestrogen receptor-positive cells in normal nonlactating human breast tissue
21. Breast cancer (2)
22. Progestin stimulation of thymidine kinase in the human breast cell line T47D
23. The role of progestins and antiprogestins in the treatment of breast cancer
24. Steroid hormones and cancer. II. Lessons from experimental systems
25. Endocrine aspects of endometrial cancer
26. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
27. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
28. The effect of age and menstrual cycle upon proliferative activity of the normal human breast
29. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques
30. p53 expression in breast and endometrium during estrogen an tamoxifen treatment of surgically postmenopausal cynomolgous macaques
31. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
32. Mammographic breast density during hormone replacement therapy: Differences according to treatment
33. Androstenedione may be a more important precursor of tissue dihydrotestosterone than testosterone in women
34. Androgens induce divergent proliferative responses in human breast cell lines
35. Clinical experience of drug treatments for mastalgia